57 research outputs found
The combined use of imaging approaches to assess drug release from multicomponent solid dispersions
PURPOSE: Imaging methods were used as tools to provide an understanding of phenomena that occur during dissolution experiments, and ultimately to select the best ratio of two polymers in a matrix in terms of enhancement of the dissolution rate and prevention of crystallization during dissolution. METHODS: Magnetic resonance imaging, ATR-FTIR spectroscopic imaging and Raman mapping have been used to study the release mechanism of a poorly water soluble drug, aprepitant, from multicomponent amorphous solid dispersions. Solid dispersions were prepared based on the combination of two selected polymers - Soluplus, as a solubilizer, and PVP, as a dissolution enhancer. Formulations were prepared in a ratio of Soluplus:PVP 1:10, 1:5, 1:3, and 1:1, in order to obtain favorable properties of the polymer carrier. RESULTS: The crystallization of aprepitant during dissolution has occurred to a varying degree in the polymer ratios 1:10, 1:5, and 1:3, but the increasing presence of Soluplus in the formulation delayed the onset of crystallization. The Soluplus:PVP 1:1 solid dispersion proved to be the best matrix studied, combining the abilities of both polymers in a synergistic manner. CONCLUSIONS: Aprepitant dissolution rate has been significantly enhanced. This study highlights the benefits of combining imaging methods in order to understand the release process
The Combined Use of Imaging Approaches to Assess Drug Release from Multicomponent Solid Dispersions
Demonstration of the specific action of a factor formed and released during incubation of lymphoid cells from a sensitized animal with antigen
Lymphocyte nucleoli activation as a marker of autoimmune disorder development. I. Observation in NZB mice.
An increased number of lymphocytes with nucleoli synthesizing RNA was found in blood and lymph nodes of aged NZB mice who developed an autoimmune disease. This was not observed in young NZB mice and in 40NX mice where no immune disorders were noted
- …